Sousa Mafalda, Pinho Rolando, Proença Luísa, Silva Joana, Ponte Ana, Rodrigues Jaime, Carvalho João
Gastroenterology Department, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal.
GE Port J Gastroenterol. 2017 May;24(3):122-128. doi: 10.1159/000452697. Epub 2016 Nov 30.
Self-expanding metallic stents (SEMS) for palliative purposes in malignant colonic obstruction are an alternative to surgery that has gained popularity over time.
We performed a retrospective study of patients submitted to SEMS for palliation of obstructing malignant colorectal cancer from 2005 to 2015 to evaluate predictive clinical factors for complications and mortality.
Forty-five patients with high rates of technical and clinical success were included (97.8 and 95.6%, respectively), with complications occurring in 17.8% (8.9% perforations, 4.4% obstructions, and 4.4% migrations). The length of the stenosis was superior in patients with complications ( = 0.01); 11.1% of patients had a re-intervention (2.2% surgery and 8.9% placement of another SEMS). Relief of obstruction without intervention was maintained until death in 77.8% of patients and in 81.4% of patients who had immediate clinical success. The mortality rate was 37.2% at 30 days, 56.5% at 60 days, and 87.5% at 1 year. There were no predictors of survival identified, including age, sex, tumor stage, metastasis, or complications of the procedure.
In this study, SEMS placement was associated with a high rate of technical and clinical success and a low rate of complications, being an option to palliate patients with obstructive neoplasia. The length of the stenosis was associated with a greater risk of complications. The majority of stent-related complications can be managed successfully without surgery.
用于缓解恶性结肠梗阻的自膨式金属支架(SEMS)是一种手术替代方案,随着时间的推移越来越受欢迎。
我们对2005年至2015年因梗阻性恶性结直肠癌接受SEMS置入以缓解症状的患者进行了一项回顾性研究,以评估并发症和死亡率的预测临床因素。
纳入了45例技术成功率和临床成功率较高的患者(分别为97.8%和95.6%),并发症发生率为17.8%(穿孔8.9%、梗阻4.4%、移位4.4%)。并发症患者的狭窄长度更长(P = 0.01);11.1%的患者需要再次干预(手术2.2%,再次置入SEMS 8.9%)。77.8%的患者在无干预的情况下梗阻缓解直至死亡,即时临床成功的患者中这一比例为81.4%。30天死亡率为37.2%,60天为56.5%,1年为87.5%。未发现生存的预测因素,包括年龄、性别、肿瘤分期、转移或手术并发症。
在本研究中,SEMS置入技术成功率和临床成功率高,并发症发生率低,是缓解梗阻性肿瘤患者症状的一种选择。狭窄长度与并发症风险增加相关。大多数支架相关并发症无需手术即可成功处理。